Abstract
Background. HLA genes play a role in the predisposition of several diseases. The aim was to
analyze the prevalence of HLA class I phenotypes and HLA-DRB1
Background. HLA genes play a role in the predisposition of several diseases. The aim was to
analyze the prevalence of HLA class I phenotypes and HLA-DRB1
M W Greaves, “Urticaria,” Clinical Allergy and Immunology, vol. 16, pp. 381–400, 2002.
View at: Google ScholarC E Grattan, “The urticaria spectrum: recognition of clinical patterns can help management,” Clinical and Experimental Dermatology, vol. 29, no. 3, pp. 217–221, 2004.
View at: Publisher Site | Google ScholarC E Grattan, R A Sabroe, and M W Greaves, “Chronic urticaria,” Journal of the American Academy of Dermatology, vol. 46, no. 5, pp. 645–657, 2002.
View at: Publisher Site | Google ScholarA P Kaplan, “Chronic urticaria: pathogenesis and treatment,” Journal of Allergy and Clinical Immunology, vol. 114, no. 3, pp. 465–474, 2004.
View at: Publisher Site | Google ScholarG Di Lorenzo, M L Pacor, P Mansueto et al., “Food-additive-induced urticaria: a survey of 838 patients with recurrent chronic idiopathic urticaria,” International Archives of Allergy and Immunology, vol. 138, no. 3, pp. 235–242, 2005.
View at: Publisher Site | Google ScholarJ G Bodmer, S G Marsh, E D Albert et al., “Nomenclature for factors of the HLA system, 1996,” Human Immunology, vol. 53, no. 1, pp. 98–128, 1997.
View at: Publisher Site | Google ScholarH G Rammensee, T Friede, and S Stevanovic, “MHC ligands and peptide motifs: first listing,” Immunogenetics, vol. 41, no. 4, pp. 178–228, 1995.
View at: Publisher Site | Google ScholarR Heard, “HLA and autoimmune disease,” in HLA and Disease, R Lechler, Ed., pp. 123–151, Academic Press, London, UK, 1994.
View at: Google ScholarG Nuki, “Ankylosing spondylitis, HLA B27, and beyond,” Lancet, vol. 351, no. 9105, pp. 767–769, 1998.
View at: Publisher Site | Google ScholarG Di Lorenzo, M L Pacor, P Mansueto et al., “Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria,” Journal of Allergy and Clinical Immunology, vol. 114, no. 3, pp. 619–625, 2004.
View at: Publisher Site | Google ScholarG Di Lorenzo, M L Pacor, A M Vignola et al., “Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients,” Allergy, vol. 57, no. 12, pp. 1180–1186, 2002.
View at: Publisher Site | Google ScholarM L Pacor, G Di Lorenzo, D Biasi, M Barbagallo, and R Corrocher, “Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs,” Clinical and Experimental Allergy, vol. 32, no. 3, pp. 397–400, 2002.
View at: Publisher Site | Google ScholarM L Pacor, G Di Lorenzo, and R Corrocher, “Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid,” Clinical and Experimental Allergy, vol. 31, no. 10, pp. 1607–1614, 2001.
View at: Publisher Site | Google ScholarS H Kim, J H Choi, K W Lee et al., “The human leucocyte antigen-0201 haplotype may be a strong genetic marker for aspirin-induced urticaria,” Clinical and Experimental Allergy, vol. 35, no. 3, pp. 339–344, 2005.
View at: Publisher Site | Google ScholarB F O'Donnell, C M O'Neill, D M Francis et al., “Human leucocyte antigen class II associations in chronic idiopathic urticaria,” British Journal of Dermatology, vol. 140, no. 5, pp. 853–858, 1999.
View at: Publisher Site | Google ScholarP Oztas, M Onder, S Gonen, M O Oztas, and O Soylemezoglu, “Is there any relationship between human leucocyte antigen class II and chronic urticaria? (chronic urticaria and HLA class II),” Yonsei Medical Journal, vol. 45, no. 3, pp. 392–395, 2004.
View at: Google ScholarJ C Roujeau, T N Huynh, C Bracq, J C Guillaume, J Revuz, and R Touraine, “Genetic susceptibility to toxic epidermal necrolysis,” Archives of Dermatology, vol. 123, no. 9, pp. 1171–1173, 1987.
View at: Publisher Site | Google ScholarJ C Roujeau, C Bracq, N T Huyn, E Chaussalet, C Raffin, and N Duedari, “HLA phenotypes and bullous cutaneous reactions to drugs,” Tissue Antigens, vol. 28, no. 4, pp. 251–254, 1986.
View at: Google ScholarS-I Hung, W-H Chung, L-B Liou et al., “5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 4134–4139, 2005.
View at: Publisher Site | Google ScholarC S Falk and D J Schendel, “HLA-C revisited. Ten years of change,” Immunologic Research, vol. 16, no. 2, pp. 203–214, 1997.
View at: Google Scholar